Early Warning System

IFC-49742
India Life Sciences Fund IV



Early Warning System India Life Sciences Fund IV

Quick Facts

Countries	India
Financial Institutions	International Finance Corporation (IFC)
Status	Proposed
Bank Risk Rating	В
Borrower	India Life Sciences Fund IV
Sectors	Finance, Industry and Trade
Investment Type(s)	Equity
Investment Amount (USD)	\$ 25.00 million
Project Cost (USD)	\$ 325.00 million

Project Description

According to the Bank's website, IFC proposes an equity investment of up to US\$25 million in India Life Sciences Fund IV, a private equity fund (PE) fund focused on providing growth capital to small and mid-market healthcare companies across (i) pharmaceuticals; (ii) healthcare delivery; (iii) medtech; (iv) specialty ingredients; (v) animal health; and (vi) other allied areas, and together with India Life Sciences Fund IV Domestic (Domestic Fund) is targeting US\$325 million in total commitments. The Fund is expected to size its average ticket per company in the range of US\$10-50 million in 12-15 companies.

Early Warning System Project Analysis

The Fund will not invest in activities on IFC Exclusion List, coal related projects, and any higher risk activities that may include involuntary resettlement, risk of adverse impacts on indigenous peoples, significant risks to or impacts on the environment, community health and safety, biodiversity, cultural heritage, risk of significant retrenchment or significant occupational health and safety risks. The main E&S risks and impacts of this Project derive from activities of Fund's investee companies and their E&S capacity and systems in place to manage these risks as well as the fund manager's capacity to adequately assess E&S risks, require corrective actions where needed, and monitor their implementation. Overall, the E&S risk of the proposed investment is medium, and the project is categorized as FI-2 according to IFC's Policy on Environmental and Social Sustainability.

Investment Description

• International Finance Corporation (IFC)

The Fund, together with the Domestic Fund, is seeking to raise US\$325 million in aggregate capital commitments. IFC proposes an equity investment of up to US\$25 million in the Fund (capped at 19.99% of the total commitments).

Private Actors Description

The Fund will be managed by Invascent ILSF Manager LLP ("Invascent" or the "Fund Manager"), a limited liability partnership under the Limited Liability Partnership Act, 2008. The Fund will engage Invascent to carry out investment management and administrative duties.



Early Warning System India Life Sciences Fund IV

Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	InvAscent ILSF Manager LLP	Parent Company	-

Contact Information

Invascent ILSF Manager LLP Hariharnath Buggana Chairman and Managing Director

Hari.buggana@invascent.com

ACCESS TO INFORMATION

You can submit a request for information disclosure at: https://disclosures.ifc.org/#/inquiries

If you believe that your request for information from IFC has been unreasonably denied, or that this Policy has been interpreted incorrectly, you can submit a complaint at the link above to IFC's Access to Information Policy Advisor, who reports directly to IFC's Executive Vice President.

ACCOUNTABILITY MECHANISM OF IFC/MIGA

The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at CAO@worldbankgroup.org You can learn more about the CAO and how to file a complaint at http://www.cao-ombudsman.org